Phathom Pharmaceuticals (PHAT) Cash from Investing Activities (2019 - 2026)
Phathom Pharmaceuticals (PHAT) reported Cash from Investing Activities of -$61000.0 for Q1 2026, down 238.89% year-over-year from $43920.0 in Q1 2025, and up 29.89% quarter-over-quarter from -$87000.0 in Q4 2025.
Phathom Pharmaceuticals (PHAT) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 8 years of Cash from Investing Activities data on file, last reported at -$61000.0 in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$61000.0, down 238.89% year-over-year; the trailing twelve-month figure through Mar 2026 was -$272000.0 (down 140.71% YoY), and the FY2025 annual result was -$229000.0, down 69.63% from the prior year.
- Cash from Investing Activities climbed to -$61000.0 in Q1 2026 per PHAT's latest filing, from -$87000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$5000.0 in Q4 2024 and troughed at -$939000.0 in Q3 2023.
- A 5-year average of -$182352.9 and a median of -$67000.0 in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities soared 98.95% in 2024, then plunged 1640.0% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at -$412000.0 in 2022, then retreated by 15.29% to -$475000.0 in 2023, then soared by 98.95% to -$5000.0 in 2024, then sank by 1640.0% to -$87000.0 in 2025, then rose by 29.89% to -$61000.0 in 2026.
- Business Quant data shows PHAT's Cash from Investing Activities at -$61000.0 in Q1 2026, -$87000.0 in Q4 2025, and -$27000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn | -61,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61,000.00 |
| Mar 31, 2026 | -61,000.00 |
| Dec 31, 2025 | -87,000.00 |
| Dec 31, 2025 | -87,000.00 |
| Sep 30, 2025 | -27,000.00 |
| Sep 30, 2025 | -27,000.00 |
| Jun 30, 2025 | -97,000.00 |
| Jun 30, 2025 | -97,000.00 |
| Mar 31, 2025 | -18,000.00 |
| Mar 31, 2025 | -18,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Sep 30, 2024 | -44,000.00 |
| Sep 30, 2024 | -44,000.00 |
| Jun 30, 2024 | -46,000.00 |
| Jun 30, 2024 | -46,000.00 |
| Mar 31, 2024 | -40,000.00 |
| Mar 31, 2024 | -40,000.00 |
| Dec 31, 2023 | -475,000.00 |
| Dec 31, 2023 | -475,000.00 |